PubMed

Effect of RU486 on Hepatic and Adipocyte Gene Expression Improves Diabetes Control in Obesity-type 2 Diabetes.

Taylor AI, Frizzell N, McKillop AM, Flatt PR, Gault VA.

Horm Metab Res. 2009 Aug 10. [Epub ahead of print]PMID: 19670152 [PubMed - as supplied by publisher]Related articles

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR, Gault VA.

Biochem Pharmacol. 2009 Oct 15;78(8):1008-16. Epub 2009 Jun 10.PMID: 19523458 [PubMed - indexed for MEDLINE]Related articles

Mass spectrometric characterisation and quantitation of selected low molecular mass compounds from the venom of Haplopelma lividum (Theraphosidae).

Moore S, Smyth WF, Gault VA, O'Kane E, McClean S.

Rapid Commun Mass Spectrom. 2009 Jun;23(12):1747-55.PMID: 19437423 [PubMed - indexed for MEDLINE]Related articles

Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance.

Kerr BD, Irwin N, Flatt PR, Gault VA.

Peptides. 2009 Feb;30(2):219-25. Epub 2008 Nov 5.PMID: 19026698 [PubMed - indexed for MEDLINE]Related articles

(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR.

Br J Pharmacol. 2008 Nov;155(5):690-701. Epub 2008 Aug 11.PMID: 18695644 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.

Gault VA, Hölscher C.

Eur J Pharmacol. 2008 Jun 10;587(1-3):112-7. Epub 2008 Mar 29.PMID: 18466898 [PubMed - indexed for MEDLINE]Related articles

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.

Gault VA, Kerr BD, Irwin N, Flatt PR.

Biochem Pharmacol. 2008 Jun 15;75(12):2325-33. Epub 2008 Mar 26.PMID: 18455149 [PubMed - indexed for MEDLINE]Related articles

Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.

McClean PL, Gault VA, Irwin N, McCluskey JT, Flatt PR.

Diabetes Obes Metab. 2008 Apr;10(4):336-42.PMID: 18333892 [PubMed - indexed for MEDLINE]Related articles

Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.

Gault VA, Hölscher C.

J Neurophysiol. 2008 Apr;99(4):1590-5. Epub 2008 Jan 30.PMID: 18234983 [PubMed - indexed for MEDLINE]Related articlesFree article

Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.

Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA.

Biol Chem. 2008 Apr;389(4):441-5.PMID: 18225986 [PubMed - indexed for MEDLINE]Related articles

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.

McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR.

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1746-55. Epub 2007 Sep 11.PMID: 17848629 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes.

Gault VA, McClean PL, Irwin N, Power GJ, McCluskey JT, Flatt PR.

Pancreas. 2007 Jul;35(1):73-9.PMID: 17575548 [PubMed - indexed for MEDLINE]Related articles

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR.

Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. Epub 2007 May 13.PMID: 17573070 [PubMed - indexed for MEDLINE]Related articles

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR.

Diabetologia. 2007 Aug;50(8):1752-62. Epub 2007 Jun 9.PMID: 17558485 [PubMed - indexed for MEDLINE]Related articles

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR.

Diabetologia. 2007 Jul;50(7):1532-40. Epub 2007 May 8.PMID: 17486314 [PubMed - indexed for MEDLINE]Related articles

Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists.

Gault VA, Hunter K, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Flatt PR.

Arch Biochem Biophys. 2007 May 15;461(2):263-74. Epub 2007 Mar 28.PMID: 17428436 [PubMed - indexed for MEDLINE]Related articles

Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning.

Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA.

Eur J Pharmacol. 2007 Apr 30;561(1-3):85-90. Epub 2007 Feb 1.PMID: 17320856 [PubMed - indexed for MEDLINE]Related articles

Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.

Irwin N, McClean PL, Cassidy RS, O'harte FP, Green BD, Gault VA, Harriott P, Flatt PR.

Diabetes Metab Res Rev. 2007 Oct;23(7):572-9.PMID: 17315241 [PubMed - indexed for MEDLINE]Related articles

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

O'Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR.

Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1674-82. Epub 2007 Feb 13.PMID: 17299087 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

Parker JC, Irwin N, Lavery KS, Green BD, O'Harte FP, Gault VA, Flatt PR.

Biol Chem. 2007 Feb;388(2):221-6.PMID: 17261085 [PubMed - indexed for MEDLINE]Related articles

Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.

Gault VA, Hunter K, Irwin N, Greer B, Green BD, Harriott P, O'Harte FP, Flatt PR.

Biol Chem. 2007 Feb;388(2):173-9.PMID: 17261080 [PubMed - indexed for MEDLINE]Related articles

Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background.

Gengler S, Gault VA, Harriott P, Hölscher C.

Exp Brain Res. 2007 Jun;179(4):621-30. Epub 2006 Dec 15.PMID: 17171334 [PubMed - indexed for MEDLINE]Related articles

Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.

Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.

J Endocrinol. 2006 Oct;191(1):93-100.PMID: 17065392 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR.

Eur J Pharmacol. 2006 Oct 10;547(1-3):192-9. Epub 2006 Jul 27.PMID: 16945366 [PubMed - indexed for MEDLINE]Related articles

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

Irwin N, Clarke GC, Green BD, Greer B, Harriott P, Gault VA, O'Harte FP, Flatt PR.

Biochem Pharmacol. 2006 Sep 14;72(6):719-28. Epub 2006 Jul 20.PMID: 16859646 [PubMed - indexed for MEDLINE]Related articles

Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice.

Green BD, Irwin N, Cassidy RS, Gault VA, Flatt PR.

Peptides. 2006 Sep;27(9):2343-9. Epub 2006 May 24.PMID: 16730098 [PubMed - indexed for MEDLINE]Related articles

Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).

Irwin N, Green BD, Parker JC, Gault VA, O'Harte FP, Flatt PR.

Regul Pept. 2006 Jul 15;135(1-2):45-53. Epub 2006 May 3.PMID: 16675042 [PubMed - indexed for MEDLINE]Related articles

NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water.

Alaña I, Parker JC, Gault VA, Flatt PR, O'Harte FP, Malthouse JP, Hewage CM.

J Biol Chem. 2006 Jun 16;281(24):16370-6. Epub 2006 Apr 18.PMID: 16621806 [PubMed - indexed for MEDLINE]Related articlesFree article

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

Irwin N, O'Harte FP, Gault VA, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR.

J Med Chem. 2006 Feb 9;49(3):1047-54.PMID: 16451070 [PubMed - indexed for MEDLINE]Related articles

Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice.

Irwin N, Green BD, Gault VA, Harriot P, O'Harte FP, Flatt PR.

Exp Gerontol. 2006 Feb;41(2):151-6. Epub 2005 Dec 27.PMID: 16378704 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

Irwin N, Gault VA, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR, O'Harte FP.

Biol Chem. 2005 Jul;386(7):679-87.PMID: 16207089 [PubMed - indexed for MEDLINE]Related articles

Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice.

Irwin N, Green BD, Gault VA, Cassidy RS, O'Harte FP, Harriott P, Flatt PR.

Peptides. 2006 Apr;27(4):893-900. Epub 2005 Sep 21.PMID: 16181707 [PubMed - indexed for MEDLINE]Related articles

A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.

Green BD, Gault VA, O'Harte FP, Flatt PR.

Diabetes Obes Metab. 2005 Sep;7(5):595-604.PMID: 16050953 [PubMed - indexed for MEDLINE]Related articles

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.

Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR.

Diabetes. 2005 Aug;54(8):2436-46.PMID: 16046312 [PubMed - indexed for MEDLINE]Related articlesFree article

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

Irwin N, Green BD, Mooney MH, Greer B, Harriott P, Bailey CJ, Gault VA, O'Harte FP, Flatt PR.

J Pharmacol Exp Ther. 2005 Sep;314(3):1187-94. Epub 2005 May 27.PMID: 15923344 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.

Green BD, Irwin N, Gault VA, Bailey CJ, O'Harte FP, Flatt PR.

J Endocrinol. 2005 May;185(2):307-17.PMID: 15845923 [PubMed - indexed for MEDLINE]Related articlesFree article

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

Irwin N, Green BD, Gault VA, Greer B, Harriott P, Bailey CJ, Flatt PR, O'Harte FP.

J Med Chem. 2005 Feb 24;48(4):1244-50.PMID: 15715491 [PubMed - indexed for MEDLINE]Related articles

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

Green BD, Gault VA, O'harte FP, Flatt PR.

Curr Pharm Des. 2004;10(29):3651-62. Review.PMID: 15579061 [PubMed - indexed for MEDLINE]Related articles

NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide.

Alaña I, Hewage CM, Malthouse JP, Parker JC, Gault VA, O'Harte FP.

Biochem Biophys Res Commun. 2004 Dec 3;325(1):281-6.PMID: 15522230 [PubMed - indexed for MEDLINE]Related articles

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.

Irwin N, Gault VA, Green BD, Greer B, McCluskey JT, Harriott P, O'Harte FP, Flatt PR.

Biol Chem. 2004 Sep;385(9):845-52.PMID: 15493880 [PubMed - indexed for MEDLINE]Related articles

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.

Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.

Arch Biochem Biophys. 2004 Aug 15;428(2):136-43.PMID: 15246869 [PubMed - indexed for MEDLINE]Related articles

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR.

Biol Chem. 2004 Feb;385(2):169-77.PMID: 15101559 [PubMed - indexed for MEDLINE]Related articles

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR.

J Endocrinol. 2004 Mar;180(3):379-88.PMID: 15012592 [PubMed - indexed for MEDLINE]Related articlesFree article

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).

Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

Metabolism. 2004 Feb;53(2):252-9.PMID: 14767880 [PubMed - indexed for MEDLINE]Related articles

N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression.

Liu HK, Green BD, Gault VA, McCluskey JT, McClenaghan NH, O'Harte FP, Flatt PR.

Cell Biol Int. 2004;28(1):69-73.PMID: 14759771 [PubMed - indexed for MEDLINE]Related articles

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

Biol Chem. 2003 Dec;384(12):1543-51.PMID: 14719796 [PubMed - indexed for MEDLINE]Related articles

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

J Mol Endocrinol. 2003 Dec;31(3):529-40.PMID: 14664713 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

Gault VA, O'Harte FP, Flatt PR.

Neuropeptides. 2003 Oct;37(5):253-63. Review.PMID: 14607102 [PubMed - indexed for MEDLINE]Related articles

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

Gault VA, Flatt PR, O'Harte FP.

Biochem Biophys Res Commun. 2003 Aug 22;308(2):207-13. Review.PMID: 12901855 [PubMed - indexed for MEDLINE]Related articles

Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.

Gault VA, O'Harte FP, Harriott P, Flatt PR.

Metabolism. 2003 Jun;52(6):679-87.PMID: 12800091 [PubMed - indexed for MEDLINE]Related articles